These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38111796)

  • 1. The involvement of brain regions associated with lower KPS and shorter survival time predicts a poor prognosis in glioma.
    Bao H; Wang H; Sun Q; Wang Y; Liu H; Liang P; Lv Z
    Front Neurol; 2023; 14():1264322. PubMed ID: 38111796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
    Karsy M; Guan J; Huang LE
    J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1
    Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X
    Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
    Ostrom QT; Shoaf ML; Cioffi G; Waite K; Kruchko C; Wen PY; Brat DJ; Barnholtz-Sloan JS; Iorgulescu JB
    Neuro Oncol; 2023 Apr; 25(4):799-807. PubMed ID: 35994777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
    Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH
    Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.
    Saito T; Sugiyama K; Hama S; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
    Neurosurg Rev; 2018 Apr; 41(2):621-628. PubMed ID: 28887717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses.
    Liu YQ; Wu F; Li JJ; Li YF; Liu X; Wang Z; Chai RC
    Front Oncol; 2019; 9():1433. PubMed ID: 31921684
    [No Abstract]   [Full Text] [Related]  

  • 8. ACTC1 as an invasion and prognosis marker in glioma.
    Ohtaki S; Wanibuchi M; Kataoka-Sasaki Y; Sasaki M; Oka S; Noshiro S; Akiyama Y; Mikami T; Mikuni N; Kocsis JD; Honmou O
    J Neurosurg; 2017 Feb; 126(2):467-475. PubMed ID: 27081897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
    Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
    J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[
    Bauer EK; Stoffels G; Blau T; Reifenberger G; Felsberg J; Werner JM; Lohmann P; Rosen J; Ceccon G; Tscherpel C; Rapp M; Sabel M; Filss CP; Shah NJ; Neumaier B; Fink GR; Langen KJ; Galldiks N
    Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1486-1495. PubMed ID: 32034446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of STAT3 gene expression in patients with glioblastoma tumors: a study from Western India.
    Trivedi T; Panchal K; Bhalala N; Trivedi P
    J Egypt Natl Canc Inst; 2022 Jul; 34(1):30. PubMed ID: 35844028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter Progression Free survival? A clinical and Molecular analytic investigation.
    Armocida D; Frati A; Salvati M; Santoro A; Pesce A
    Clin Neurol Neurosurg; 2020 Nov; 198():106126. PubMed ID: 32861131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
    Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.
    Ohba S; Yamada Y; Murayama K; Sandika E; Sasaki H; Yamada S; Abe M; Hasegawa M; Hirose Y
    World Neurosurg; 2019 Jun; 126():e1042-e1049. PubMed ID: 30878754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and radiographic characteristics of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma: a single institution review.
    Grogan D; Bray DP; Cosgrove M; Boucher A; Erwood A; Linder DF; Mendoza P; Morales B; Pradilla G; Nduom EK; Neill S; Olson JJ; Hoang KB
    J Neurooncol; 2022 Mar; 157(1):187-195. PubMed ID: 35212929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
    Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
    Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic utility of genetic alterations in distinguishing IDH-wildtype glioblastoma from lower-grade gliomas: Insight from next-generation sequencing analysis of 479 cases.
    Lee B; Hwang S; Bae H; Choi KH; Suh YL
    Brain Pathol; 2024 Jan; ():e13234. PubMed ID: 38217295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.
    Lu VM; O'Connor KP; Shah AH; Eichberg DG; Luther EM; Komotar RJ; Ivan ME
    J Neurooncol; 2020 Jun; 148(2):221-229. PubMed ID: 32385699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Yoon BH; Park JS; Kang S; Kwon NJ; Lee KS; Kim CY; Choe G
    Br J Neurosurg; 2023 Oct; 37(5):1233-1236. PubMed ID: 33095064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.